Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis

Sepsis is an extensive life‐threatening illness that occurs due to an abnormal host response that extends through the initial storm of inflammation and oxidative stress and terminates at the late stage of immunosuppression. Among global intensive care units, sepsis‐induced acute kidney injury is rep...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Fundamental & clinical pharmacology 2022-04, Vol.36 (2), p.286-295
Hauptverfasser: Al‐Kadi, Alaa, El‐Daly, Mahmoud, El‐Tahawy, Nashwa F. G., Khalifa, Mohamed Montaser A., Ahmed, Al‐Shaimaa F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 295
container_issue 2
container_start_page 286
container_title Fundamental & clinical pharmacology
container_volume 36
creator Al‐Kadi, Alaa
El‐Daly, Mahmoud
El‐Tahawy, Nashwa F. G.
Khalifa, Mohamed Montaser A.
Ahmed, Al‐Shaimaa F.
description Sepsis is an extensive life‐threatening illness that occurs due to an abnormal host response that extends through the initial storm of inflammation and oxidative stress and terminates at the late stage of immunosuppression. Among global intensive care units, sepsis‐induced acute kidney injury is reported with high mortality rate. The purpose of this study was to evaluate the protective effect of the renin angiotensin aldosterone system (RAAS) inhibition on sepsis outcomes. Cecal ligation and puncture (CLP) procedure was applied for sepsis induction. The experimental design constituted of five groups of rats: sham, CLP‐nontreated and CLP‐treated with ramipril (10 mg/kg, p.o.), losartan (20 mg/kg, i.p.) and spironolactone (25 mg/kg, p.o.). Twenty‐four hours after surgery, rats were euthanized for blood and tissue samples, which were used for assessment of serum inflammatory markers, and oxidative stress parameters, as well as to kidney function parameters. The tissue samples were used for histological and caspase‐3 assessment. A survival study was conducted using another set of animals. Our results showed that the different RAAS inhibitors showed protective effects evidenced by enhanced overall survival following sepsis (80% in ramipril and spironolactone‐treated and 60% in losartan‐treated vs. 10% in the septic group), in addition to improved renal function parameters and reduction of oxidative stress and inflammation. The timely use of RAAS inhibitors during sepsis might represent a new therapeutic approach in septic patient.
doi_str_mv 10.1111/fcp.12718
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2555347075</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638248019</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3538-3983290b809d40615b0205457a682c255856c7dcfef8a4051208ec22af65fce43</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi0EokNhwQsgS2zoYlpf4kuW1YgWpEqwgLXlOMcdD4kd7GSqeQ8eGE-nsEDCmyNL3__pHP0IvaXkktZ35d10SZmi-hla0UaxtWZEPkcroqRa81bTM_SqlB0hVBEqX6Iz3nDSEtmu0K_reB_SDLGEiO3QpzJDThFwiNvQhTnlgsM45bQHXJa8D3s7YBt7bEcYQsp2Bvwj9BEONbFb8nH0i4MedwdcYCqh4Hmb03K_rflpylBKSBEnX0E_2HG08_H_qJzSNKeaeI1eeDsUePM0z9H3m4_fNp_Wd19uP2-u79aOC66Pl3HWkk6Ttm-IpKIjjIhGKCs1c0wILaRTvfPgtW2IoIxocIxZL4V30PBz9OHkrff9XKDMZgzFwTDYCGkppioEbxRRoqLv_0F3acmxbmeY5Jo1mtC2UhcnyuVUSgZvphxGmw-GEnOsytSqzGNVlX33ZFy6Efq_5J9uKnB1Ah7CAIf_m8zN5utJ-RvJ-qBP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638248019</pqid></control><display><type>article</type><title>Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Al‐Kadi, Alaa ; El‐Daly, Mahmoud ; El‐Tahawy, Nashwa F. G. ; Khalifa, Mohamed Montaser A. ; Ahmed, Al‐Shaimaa F.</creator><creatorcontrib>Al‐Kadi, Alaa ; El‐Daly, Mahmoud ; El‐Tahawy, Nashwa F. G. ; Khalifa, Mohamed Montaser A. ; Ahmed, Al‐Shaimaa F.</creatorcontrib><description>Sepsis is an extensive life‐threatening illness that occurs due to an abnormal host response that extends through the initial storm of inflammation and oxidative stress and terminates at the late stage of immunosuppression. Among global intensive care units, sepsis‐induced acute kidney injury is reported with high mortality rate. The purpose of this study was to evaluate the protective effect of the renin angiotensin aldosterone system (RAAS) inhibition on sepsis outcomes. Cecal ligation and puncture (CLP) procedure was applied for sepsis induction. The experimental design constituted of five groups of rats: sham, CLP‐nontreated and CLP‐treated with ramipril (10 mg/kg, p.o.), losartan (20 mg/kg, i.p.) and spironolactone (25 mg/kg, p.o.). Twenty‐four hours after surgery, rats were euthanized for blood and tissue samples, which were used for assessment of serum inflammatory markers, and oxidative stress parameters, as well as to kidney function parameters. The tissue samples were used for histological and caspase‐3 assessment. A survival study was conducted using another set of animals. Our results showed that the different RAAS inhibitors showed protective effects evidenced by enhanced overall survival following sepsis (80% in ramipril and spironolactone‐treated and 60% in losartan‐treated vs. 10% in the septic group), in addition to improved renal function parameters and reduction of oxidative stress and inflammation. The timely use of RAAS inhibitors during sepsis might represent a new therapeutic approach in septic patient.</description><identifier>ISSN: 0767-3981</identifier><identifier>EISSN: 1472-8206</identifier><identifier>DOI: 10.1111/fcp.12718</identifier><identifier>PMID: 34309069</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Aldosterone ; Aldosterone - pharmacology ; Aldosterone - therapeutic use ; Angiotensin ; Angiotensins - pharmacology ; Angiotensins - therapeutic use ; angiotensin‐II ; Animals ; Apoptosis ; Caspase ; Cecum ; CLP ; Design of experiments ; Disease Models, Animal ; Experimental design ; Hospitals ; Humans ; IL‐6 ; Immunosuppression ; Inflammation ; Inflammation - drug therapy ; Inflammation - pathology ; Inhibitors ; Intensive care units ; Kidney ; Kidneys ; losartan ; Oxidative stress ; Parameters ; Pharmacology ; ramipril ; Rats ; Renal function ; Renin ; Sepsis ; Sepsis - complications ; Sepsis - drug therapy ; spironolactone ; Survival ; TNF‐α</subject><ispartof>Fundamental &amp; clinical pharmacology, 2022-04, Vol.36 (2), p.286-295</ispartof><rights>2021 Société Française de Pharmacologie et de Thérapeutique</rights><rights>2021 Société Française de Pharmacologie et de Thérapeutique.</rights><rights>2022 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3538-3983290b809d40615b0205457a682c255856c7dcfef8a4051208ec22af65fce43</citedby><cites>FETCH-LOGICAL-c3538-3983290b809d40615b0205457a682c255856c7dcfef8a4051208ec22af65fce43</cites><orcidid>0000-0001-5971-1104 ; 0000-0001-9875-6399</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ffcp.12718$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ffcp.12718$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34309069$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al‐Kadi, Alaa</creatorcontrib><creatorcontrib>El‐Daly, Mahmoud</creatorcontrib><creatorcontrib>El‐Tahawy, Nashwa F. G.</creatorcontrib><creatorcontrib>Khalifa, Mohamed Montaser A.</creatorcontrib><creatorcontrib>Ahmed, Al‐Shaimaa F.</creatorcontrib><title>Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis</title><title>Fundamental &amp; clinical pharmacology</title><addtitle>Fundam Clin Pharmacol</addtitle><description>Sepsis is an extensive life‐threatening illness that occurs due to an abnormal host response that extends through the initial storm of inflammation and oxidative stress and terminates at the late stage of immunosuppression. Among global intensive care units, sepsis‐induced acute kidney injury is reported with high mortality rate. The purpose of this study was to evaluate the protective effect of the renin angiotensin aldosterone system (RAAS) inhibition on sepsis outcomes. Cecal ligation and puncture (CLP) procedure was applied for sepsis induction. The experimental design constituted of five groups of rats: sham, CLP‐nontreated and CLP‐treated with ramipril (10 mg/kg, p.o.), losartan (20 mg/kg, i.p.) and spironolactone (25 mg/kg, p.o.). Twenty‐four hours after surgery, rats were euthanized for blood and tissue samples, which were used for assessment of serum inflammatory markers, and oxidative stress parameters, as well as to kidney function parameters. The tissue samples were used for histological and caspase‐3 assessment. A survival study was conducted using another set of animals. Our results showed that the different RAAS inhibitors showed protective effects evidenced by enhanced overall survival following sepsis (80% in ramipril and spironolactone‐treated and 60% in losartan‐treated vs. 10% in the septic group), in addition to improved renal function parameters and reduction of oxidative stress and inflammation. The timely use of RAAS inhibitors during sepsis might represent a new therapeutic approach in septic patient.</description><subject>Aldosterone</subject><subject>Aldosterone - pharmacology</subject><subject>Aldosterone - therapeutic use</subject><subject>Angiotensin</subject><subject>Angiotensins - pharmacology</subject><subject>Angiotensins - therapeutic use</subject><subject>angiotensin‐II</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>Caspase</subject><subject>Cecum</subject><subject>CLP</subject><subject>Design of experiments</subject><subject>Disease Models, Animal</subject><subject>Experimental design</subject><subject>Hospitals</subject><subject>Humans</subject><subject>IL‐6</subject><subject>Immunosuppression</subject><subject>Inflammation</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - pathology</subject><subject>Inhibitors</subject><subject>Intensive care units</subject><subject>Kidney</subject><subject>Kidneys</subject><subject>losartan</subject><subject>Oxidative stress</subject><subject>Parameters</subject><subject>Pharmacology</subject><subject>ramipril</subject><subject>Rats</subject><subject>Renal function</subject><subject>Renin</subject><subject>Sepsis</subject><subject>Sepsis - complications</subject><subject>Sepsis - drug therapy</subject><subject>spironolactone</subject><subject>Survival</subject><subject>TNF‐α</subject><issn>0767-3981</issn><issn>1472-8206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctu1DAUhi0EokNhwQsgS2zoYlpf4kuW1YgWpEqwgLXlOMcdD4kd7GSqeQ8eGE-nsEDCmyNL3__pHP0IvaXkktZ35d10SZmi-hla0UaxtWZEPkcroqRa81bTM_SqlB0hVBEqX6Iz3nDSEtmu0K_reB_SDLGEiO3QpzJDThFwiNvQhTnlgsM45bQHXJa8D3s7YBt7bEcYQsp2Bvwj9BEONbFb8nH0i4MedwdcYCqh4Hmb03K_rflpylBKSBEnX0E_2HG08_H_qJzSNKeaeI1eeDsUePM0z9H3m4_fNp_Wd19uP2-u79aOC66Pl3HWkk6Ttm-IpKIjjIhGKCs1c0wILaRTvfPgtW2IoIxocIxZL4V30PBz9OHkrff9XKDMZgzFwTDYCGkppioEbxRRoqLv_0F3acmxbmeY5Jo1mtC2UhcnyuVUSgZvphxGmw-GEnOsytSqzGNVlX33ZFy6Efq_5J9uKnB1Ah7CAIf_m8zN5utJ-RvJ-qBP</recordid><startdate>202204</startdate><enddate>202204</enddate><creator>Al‐Kadi, Alaa</creator><creator>El‐Daly, Mahmoud</creator><creator>El‐Tahawy, Nashwa F. G.</creator><creator>Khalifa, Mohamed Montaser A.</creator><creator>Ahmed, Al‐Shaimaa F.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5971-1104</orcidid><orcidid>https://orcid.org/0000-0001-9875-6399</orcidid></search><sort><creationdate>202204</creationdate><title>Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis</title><author>Al‐Kadi, Alaa ; El‐Daly, Mahmoud ; El‐Tahawy, Nashwa F. G. ; Khalifa, Mohamed Montaser A. ; Ahmed, Al‐Shaimaa F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3538-3983290b809d40615b0205457a682c255856c7dcfef8a4051208ec22af65fce43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aldosterone</topic><topic>Aldosterone - pharmacology</topic><topic>Aldosterone - therapeutic use</topic><topic>Angiotensin</topic><topic>Angiotensins - pharmacology</topic><topic>Angiotensins - therapeutic use</topic><topic>angiotensin‐II</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>Caspase</topic><topic>Cecum</topic><topic>CLP</topic><topic>Design of experiments</topic><topic>Disease Models, Animal</topic><topic>Experimental design</topic><topic>Hospitals</topic><topic>Humans</topic><topic>IL‐6</topic><topic>Immunosuppression</topic><topic>Inflammation</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - pathology</topic><topic>Inhibitors</topic><topic>Intensive care units</topic><topic>Kidney</topic><topic>Kidneys</topic><topic>losartan</topic><topic>Oxidative stress</topic><topic>Parameters</topic><topic>Pharmacology</topic><topic>ramipril</topic><topic>Rats</topic><topic>Renal function</topic><topic>Renin</topic><topic>Sepsis</topic><topic>Sepsis - complications</topic><topic>Sepsis - drug therapy</topic><topic>spironolactone</topic><topic>Survival</topic><topic>TNF‐α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al‐Kadi, Alaa</creatorcontrib><creatorcontrib>El‐Daly, Mahmoud</creatorcontrib><creatorcontrib>El‐Tahawy, Nashwa F. G.</creatorcontrib><creatorcontrib>Khalifa, Mohamed Montaser A.</creatorcontrib><creatorcontrib>Ahmed, Al‐Shaimaa F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Fundamental &amp; clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al‐Kadi, Alaa</au><au>El‐Daly, Mahmoud</au><au>El‐Tahawy, Nashwa F. G.</au><au>Khalifa, Mohamed Montaser A.</au><au>Ahmed, Al‐Shaimaa F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis</atitle><jtitle>Fundamental &amp; clinical pharmacology</jtitle><addtitle>Fundam Clin Pharmacol</addtitle><date>2022-04</date><risdate>2022</risdate><volume>36</volume><issue>2</issue><spage>286</spage><epage>295</epage><pages>286-295</pages><issn>0767-3981</issn><eissn>1472-8206</eissn><abstract>Sepsis is an extensive life‐threatening illness that occurs due to an abnormal host response that extends through the initial storm of inflammation and oxidative stress and terminates at the late stage of immunosuppression. Among global intensive care units, sepsis‐induced acute kidney injury is reported with high mortality rate. The purpose of this study was to evaluate the protective effect of the renin angiotensin aldosterone system (RAAS) inhibition on sepsis outcomes. Cecal ligation and puncture (CLP) procedure was applied for sepsis induction. The experimental design constituted of five groups of rats: sham, CLP‐nontreated and CLP‐treated with ramipril (10 mg/kg, p.o.), losartan (20 mg/kg, i.p.) and spironolactone (25 mg/kg, p.o.). Twenty‐four hours after surgery, rats were euthanized for blood and tissue samples, which were used for assessment of serum inflammatory markers, and oxidative stress parameters, as well as to kidney function parameters. The tissue samples were used for histological and caspase‐3 assessment. A survival study was conducted using another set of animals. Our results showed that the different RAAS inhibitors showed protective effects evidenced by enhanced overall survival following sepsis (80% in ramipril and spironolactone‐treated and 60% in losartan‐treated vs. 10% in the septic group), in addition to improved renal function parameters and reduction of oxidative stress and inflammation. The timely use of RAAS inhibitors during sepsis might represent a new therapeutic approach in septic patient.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34309069</pmid><doi>10.1111/fcp.12718</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-5971-1104</orcidid><orcidid>https://orcid.org/0000-0001-9875-6399</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0767-3981
ispartof Fundamental & clinical pharmacology, 2022-04, Vol.36 (2), p.286-295
issn 0767-3981
1472-8206
language eng
recordid cdi_proquest_miscellaneous_2555347075
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Aldosterone
Aldosterone - pharmacology
Aldosterone - therapeutic use
Angiotensin
Angiotensins - pharmacology
Angiotensins - therapeutic use
angiotensin‐II
Animals
Apoptosis
Caspase
Cecum
CLP
Design of experiments
Disease Models, Animal
Experimental design
Hospitals
Humans
IL‐6
Immunosuppression
Inflammation
Inflammation - drug therapy
Inflammation - pathology
Inhibitors
Intensive care units
Kidney
Kidneys
losartan
Oxidative stress
Parameters
Pharmacology
ramipril
Rats
Renal function
Renin
Sepsis
Sepsis - complications
Sepsis - drug therapy
spironolactone
Survival
TNF‐α
title Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T10%3A02%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Angiotensin%20aldosterone%20inhibitors%20improve%20survival%20and%20ameliorate%20kidney%20injury%20induced%20by%20sepsis%20through%20suppression%20of%20inflammation%20and%20apoptosis&rft.jtitle=Fundamental%20&%20clinical%20pharmacology&rft.au=Al%E2%80%90Kadi,%20Alaa&rft.date=2022-04&rft.volume=36&rft.issue=2&rft.spage=286&rft.epage=295&rft.pages=286-295&rft.issn=0767-3981&rft.eissn=1472-8206&rft_id=info:doi/10.1111/fcp.12718&rft_dat=%3Cproquest_cross%3E2638248019%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638248019&rft_id=info:pmid/34309069&rfr_iscdi=true